September 6: The Week in Cancer News
Asian American and Pacific Islander women experience rising breast cancer incidence, and a study finds most people diagnosed with cancer will experience cognitive symptoms.
Progress Against Cancer
Asian American and Pacific Islander women experience rising breast cancer incidence, and a study finds most people diagnosed with cancer will experience cognitive symptoms.
Access to high-quality hospitals may be affected by insurance type, and the proliferation of digital tools could increase burdens on patients.
Early immunotherapy may make more liver cancer patients eligible for surgery, and the FDA approves a new use for a lung cancer treatment.
Immunotherapy may make surgery an option for patients who would be considered ineligible under traditional rules. Surgery is usually the best treatment for early-stage hepatocellular carcinoma, the most common type of liver cancer, but...
More endometrial cancer patients can now receive an immunotherapy, and taking aspirin regularly may help some people reduce their risk for colorectal cancer.
Blood test approval widens access to colorectal cancer screening option, and language barriers interrupt cancer care before it starts.
The FDA has approved dostarlimab-gxly plus chemotherapy to treat more patients with endometrial cancer. The U.S. Food and Drug Administration (FDA) has approved dostarlimab-gxly (Jemperli) in combination with the chemotherapies carboplatin and paclitaxel, followed...
The targeted therapy was approved by the FDA for use in combination with bortezomib, lenalidomide, and dexamethasone. The U.S. Food and Drug Administration (FDA) has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro), plus bortezomib, lenalidomide,...
Double mastectomy doesn’t lead to a survival advantage over lumpectomy or single mastectomy, and research explores hearing loss linked to cisplatin.
Standard screening may not catch endometrial cancer in Black women, and a cancer patient receives a voice box transplant for the first time.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now